A Multicenter, Open-label, Controlled Study to Investigate the Effect of Either LF111 or Drospirenone Chewable Tablets on Bone Mineral Density in Adolescent and Adult Women in Comparison With Non-users of Hormonal Contraceptive Methods
Latest Information Update: 13 Sep 2024
At a glance
- Drugs Drospirenone (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Chemo Research, S.L.; Insud Pharma
- 15 Jun 2023 Planned primary completion date changed from 1 Dec 2025 to 1 Jul 2026.
- 30 Jun 2022 Status changed from not yet recruiting to recruiting.
- 06 Apr 2022 New trial record